Updated on 28 July 2026
Novel Platinum-Based Drug (HJ-550 )
CEO at Shanghai Haiju Biotechnology Co., Ltd.
China
About
A first-in-class targeted bivalent platinum drug exhibits overall superior efficacy over first-line standard-of-care treatments as monotherapy and in combination, holding potential to transform first-line tumor therapeutic strategies.
Project Location
- China
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Investment / Financing Discussion
Main Project Sector
- Technology
Technology
- Bio-Tech
Total Project Value
- 10,000,001 to 25,000,000 USD
Investment Capital Required
- 500,001 to 1,000,000 USD
Interested Format of Cooperation
- Convertible Loan
- Direct Equity Investment
- Joint Venture
Preferred Financing Model
- Debt
- Equity
Type(s) of Last Financing Round of the project (if Applicable)
- Equity (private)
Main Service(s) Required
- Financial Services
- Professional Services
Financial Services
- Institutional Investment
- Investment Banking
- Mergers & Acquisition
- Private Equity & Venture Capital
Attached files
Organisation
Similar opportunities
Project
Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)
- Yes
- Yes
- Debt
- Equity
- Bio-Tech
- Technology
- Joint Venture
- Private Project
- Health Technology
- Convertible Loan
- Equity (private)
- Financial Services
- Direct Equity Investment
- 5,000,001 to 7,500,000 USD
- 1,000,001 to 2,500,000 USD
- Investment / Financing Discussion
- M&A / Strategic Acquisition Opportunity
Haiyang Wang
CEO at Shanghai Haiju Biotechnology Co., Ltd.
China
Project
Point-of-care Early Cancer Breath Testing
- No
- Yes
- Debt
- Equity
- Technology
- Private Project
- Health Technology
- Convertible Loan
- Equity (private)
- Medical Technology
- Financial Services
- Open for negotiation
- Open for Negotiation
- Minority Shareholdings
- Direct Equity Investment
- Institutional Investment
- 2,500,001 to 5,000,000 USD
- Public / Alternative Financing
- Private Equity & Venture Capital
- Investment / Financing Discussion
Grover Cheung
Founder & CEO at Qi Diagnostics Limited
China (Hong Kong)
Project
AI enabled Acceleration of Preclinical Biologic Drug Development
- No
- Yes
- Equity
- Bio-Tech
- Technology
- Private Project
- Equity (private)
- Financial Services
- Partner Identification
- Direct Equity Investment
- 10,000,001 to 25,000,000 USD
- Private Equity & Venture Capital
Kingsley Leung
Chairman & Co-founder at Great Bay Bio Limited
China (Hong Kong)